Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67
Desser et al determine if there's a societal preference for prioritizing the treatment of rare diseases that could justify ignoring cost effectiveness thresholds for orphan drugs. Results show that there is little evidence that a societal preference for rarity in itself exists. Orphan drugs--th...
Gespeichert in:
Veröffentlicht in: | BMJ 2010, Vol.341 (7774), p.c5396 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Desser et al determine if there's a societal preference for prioritizing the treatment of rare diseases that could justify ignoring cost effectiveness thresholds for orphan drugs. Results show that there is little evidence that a societal preference for rarity in itself exists. Orphan drugs--those targeting diseases with very low prevalence--often fail to meet standard cost effectiveness thresholds for public reimbursement. Debate about exempting orphan drugs from such criteria centers on whether a societal preference for rarity exists. |
---|---|
ISSN: | 0959-8138 0959-8146 1468-5833 1756-1833 |
DOI: | 10.1136/bmj.c5396 |